<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ABC Medicine: Health Store,  Medical dictionary &#187; health</title>
	<atom:link href="http://abc-medicine.com/category/health/feed" rel="self" type="application/rss+xml" />
	<link>http://abc-medicine.com</link>
	<description>Health information and Health store for best online price for medical products</description>
	<lastBuildDate>Wed, 04 Jan 2012 22:09:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Novartis: Ovarian cancer drug disappoints in trial 
    (AP)</title>
		<link>http://abc-medicine.com/novartis-ovarian-cancer-drug-disappoints-in-trial-ap.html</link>
		<comments>http://abc-medicine.com/novartis-ovarian-cancer-drug-disappoints-in-trial-ap.html#comments</comments>
		<pubDate>Thu, 27 May 2010 16:24:14 +0000</pubDate>
		<dc:creator>Yahoo! News: Health News</dc:creator>
				<category><![CDATA[Diabete]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[Medicina]]></category>

		<guid isPermaLink="false">http://ap/20100527/eu_switzerland_novartis_cancer_drug</guid>
		<description><![CDATA[AP - Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing. <a class="more-link" href="http://abc-medicine.com/novartis-ovarian-cancer-drug-disappoints-in-trial-ap.html">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<p>AP &#8211; Swiss drug maker Novartis AG said Thursday it won&#8217;t ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.</p>
]]></content:encoded>
			<wfw:commentRss>http://abc-medicine.com/novartis-ovarian-cancer-drug-disappoints-in-trial-ap.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

